Innospec (IOSP) Cash & Equivalents (2010 - 2026)

Innospec has reported Cash & Equivalents for 17 years, with the latest figure at $289.1 million in Q1 2026.

• Quarterly Cash & Equivalents fell 3.57% year-over-year to $289.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $289.1 million (down 3.57% YoY) and the FY2025 annual result came in at $292.5 million, up 1.14% from the prior year.
• Cash & Equivalents declined to $289.1 million in Q1 2026 per IOSP's latest filing, from $292.5 million in the prior quarter.
• Over five years, Cash & Equivalents peaked at $303.8 million in Q3 2024 and troughed at $71.4 million in Q2 2022.
• A 5-year average of $215.9 million and a median of $240.2 million in 2024 frame the typical range for Cash & Equivalents.
• The sharpest annual moves came in 2022 and 2023: Cash & Equivalents slipped 24.36% in 2022, then soared 132.35% in 2023.
• Over 5 years, Cash & Equivalents stood at $147.1 million in 2022, then surged by 38.48% to $203.7 million in 2023, then jumped by 41.97% to $289.2 million in 2024, then gained by 1.14% to $292.5 million in 2025, then retreated by 1.16% to $289.1 million in 2026.
• According to Business Quant data, Cash & Equivalents over the past three periods registered $289.1 million, $292.5 million, and $270.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.